Introduction Presage has created a method for evaluating the effectiveness of drugs or RNA interference agents on tumors without the constraints associated with traditional systemic administration. This approach allows pharmaceutical companies to discontinue development of ineffective compounds and identify drug targets using RNA interference without worrying about the distribution of systemically administered RNAi agents. Additionally, Presage's technology can help identify successful drug combinations by providing a more direct measurement of their efficacy. |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Fusion protein | 1 |
Monoclonal antibody | 1 |
Target |
Mechanism LAG3 inhibitors [+2] |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TLR8 agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism SAE inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date01 Mar 2024 |
Sponsor / Collaborator ![]() [+1] |
Start Date15 Oct 2021 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
MVC-101 ( CD3 x EGFR ) | Solid tumor More | Phase 2 Clinical |
Relatlimab ( LAG3 ) | Solid tumor More | Phase 1 |
TAK-676 ( STING ) | Solid tumor More | Phase 1 |
Subasumstat ( SAE ) | Head and Neck Neoplasms More | Phase 1 |
Motolimod ( TLR8 ) | Squamous Cell Carcinoma of Head and Neck More | Phase 1 |